Baseline characteristics
| Placebo | 500 Units | 1000 Units | 1500 Units | |
| Demographic details: | ||||
| No of patients | 16 | 21 | 20 | 17 |
| Age (y (SD)) | 50.7 (10.9) | 47.0 (12.2) | 54.0 (9.9) | 46.8 (10.3) |
| Females (n (%)) | 12 (75) | 16 (76) | 9 (45) | 9 (53) |
| Height (cm (SD)) | 166 (13) | 165 (10) | 171 (9) | 170 (9) |
| Weight (kg (SD)) | 60.3 (9.9) | 60.5 (14.0) | 68.2 (10.6) | 67.9 (14.1) |
| Duration of MS (y (SD)) | 16.6 (6.4) | 16.5 (7.3) | 22.9 (10.6) | 21.2 (10.6) |
| Kurtzke EDS score (median) | 7.75 | 8.00 | 7.50 | 7.50 |
| Concomitant medication: | ||||
| Skeletal muscle relaxant (n (%)) | 6 (38) | 17 (81) | 13 (65) | 9 (53) |
| Analgesics (n (%)) | 2 (13) | 7 (38) | 7 (35) | 3 (18) |
| Diazepam (n (%)) | 4 (25) | 7 (33) | 5 (25) | 6 (35) |